Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aveni Foundation
ViroMissile, Inc.
Dana-Farber Cancer Institute
AstraZeneca
Washington University School of Medicine
University of Florida
Essen Biotech
Angiex, Inc.
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
Tanabe Pharma America, Inc.
M.D. Anderson Cancer Center
AVM Biotechnology Inc
Pfizer
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Fudan University
Jonsson Comprehensive Cancer Center
Institut Bergonié
Eli Lilly and Company
NextPoint Therapeutics, Inc.
Tempus AI
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Chinese University of Hong Kong
Elevation Oncology
Labcorp Corporation of America Holdings, Inc
Cedars-Sinai Medical Center
Agenus Inc.
Rutgers, The State University of New Jersey
Agenus Inc.
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
OHSU Knight Cancer Institute
Charite University, Berlin, Germany
Prelude Therapeutics
M.D. Anderson Cancer Center
Bayer
pharmaand GmbH
Kineta Inc.
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
MacroGenics
Charite University, Berlin, Germany
SpeciCare